Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
By L. Fardet, L. Galicier, O. Lambotte, C. Marzac, C. Aumont, Doumit Chahwan, P. Coppo, G. Hejblum. Arthritis & Rheumatology, 2014
1,271 citations recorded by the source corpus.
Subfields: Hematology, Pediatrics, Perinatology and Child Health, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/7f595455bd8b76d790afc813984ed761f18c9c21
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- B. Shakoory
- S. Opal
- R. Q. Cron
- C. A. Dinarello
- Richard L. Amdur
- J. Carcillo
- W. W. Chatham
- Huaqing Zhao
Citations in the corpus
- COVID-19: consider cytokine storm syndromes and immunosuppression (2020, neutral): “7 The HScore 11 generates a probability for the presence of secondary HLH. HScores greater than 169 are 93% sensitive and 86% specific for HLH. Note that bone marrow haemophagocytosis is not mandatory for a diagnosis of HLH. HScores can be calculated using an online HScore calculator. 11 HLH=haemoph”
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure (2020, neutral): “HScore is proposed as a classification tool for secondary MAS, and values more than 169 are highly diagnostic (Fardet et al., 2014).”
- COVID-19 and Multiorgan Response (2020, neutral): “Additionally, the number of suppressor and helper T cells, B cells, and NK 12 Curr Probl Cardiol, August 2020 cells were decreased in the severe group.60 Septic shock is also reported in 4%-8% of patients in several case series.61 Therefore, it is paramount for all patients with severe COVID-19 to b”
- Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial (2016, background): “In recent studies to develop validated case definitions for MAS, attributes of HBD (liver enzyme elevation) and DIC (hypofibrinogenemia and thrombocytopenia) are consistently among the most prevalent clinical features encountered in patients with presumed MAS (18, 20).”